Paris-based EG 427 closes €18 million Series A to further develop gene therapies for chronic disease

Published on July 14, 2023

EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announced the final closing of a Series A financing. EG 427 raised an additional €5 million in the final closing from a combination of existing investors and new family office investors, bringing the total raised in the Series A round to €18…

This content is for members only. Visit the site and log in/register to read.

The post Paris-based EG 427 closes €18 million Series A to further develop gene therapies for chronic disease appeared first on EU-Startups.

Continue reading on website
Other news

68% of Companies Are Making This Critical Mistake in Their Approach to Hybrid Work — Are You?

July 13, 2023
It is paramount for businesses to iron out their approach to hybrid work to avoid becoming a statistic.

Swiss smart energy startup Hive Power secure €500k to integrate electrical networks in a 4D future

July 14, 2023
Hive Power, a leading provider of solutions for energy optimization, closed a new funding round totaling €500k, including strong support from Techstars, Péter Ilyés (former CEO of E.ON Italy), TiVentures, and Magility Ventures. Founded in Switzerland in 2017, Hive Power boasts a team of researchers and scientists with expertise in smart grids from SUPSI (the… This content is for members only. Visi